Thinly traded micro cap OncoCyte (OCX -40.6%) slumps on more than a 6x surge in volume in response to its announcement that it will need additional time to complete its CLIA validation study for its lung cancer liquid biopsy test DetermaVu.
The company needs to complete the study before offering the testing service to commercial customers. It originally planned to launch the it “mid-year.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.